Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $9.4 million.

  • Century Therapeutics' Non-cash Items rose 7610.22% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 7610.22%. This contributed to the annual value of $16.1 million for FY2024, which is 808.95% down from last year.
  • Latest data reveals that Century Therapeutics reported Non-cash Items of $9.4 million as of Q3 2025, which was up 7610.22% from $8.0 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Non-cash Items peaked at $38.4 million during Q1 2023, and registered a low of $3.2 million during Q3 2022.
  • Its 4-year average for Non-cash Items is $13.6 million, with a median of $9.4 million in 2025.
  • As far as peak fluctuations go, Century Therapeutics' Non-cash Items soared by 100731.45% in 2023, and later tumbled by 8844.25% in 2024.
  • Over the past 4 years, Century Therapeutics' Non-cash Items (Quarter) stood at $3.2 million in 2022, then skyrocketed by 446.75% to $17.6 million in 2023, then fell by 8.09% to $16.1 million in 2024, then tumbled by 41.7% to $9.4 million in 2025.
  • Its last three reported values are $9.4 million in Q3 2025, $8.0 million for Q2 2025, and $15.0 million during Q1 2025.